Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Zacks Investment Research Inc.
$12.00
Provider: Zacks Investment Research Inc.
$12.00
Provider: Zacks Investment Research Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alcobra Ltd announces IND submission for extended release Metadoxine to treat adults with ADHD


Friday, 7 Feb 2014 01:59pm EST 

Alcobra Ltd:Announces the submission of an Investigational New Drug Application (IND) with the U.S. FDA to initiate a Phase III clinical trial with MG01CI.Says the study is entitled A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared with Placebo in Adults with Attention Deficit/Hyperactivity Disorder (ADHD). 

Company Quote

3.93
-0.07 -1.75%
26 Dec 2014